AGI.do

Products

What will AGI do for Ambrisentan?

This classification denotes an endothelin-1 protein receptor antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HW6NV07QEC. European Medicines Agency schedules Ambrisentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25424. Ambrisentan generally arises in the molecular formula C22H22N2O4. The term AMBRISENTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule ambrisentan under HS 29335995 and SITC 51576. As of Q4 2014, AMBRISENTAN remains the US FDA Preferred Term for this commodity. Ambrisentan bears US NLM identifiers UMLS ID C1176329 and NCI Concept Code C72694. SMILES: O(C(C(Oc1nc(cc(n1)C)C)C(=O)O)(c1ccccc1)c1ccccc1)C.

How AGI delivers it

Four ways AGI delivers for Ambrisentan

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Ambrisentan, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Ambrisentan, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Ambrisentan connects

measured by

  • Active Ingredient Potencymodel
  • Compound Puritymodel
  • Content Uniformitymodel
  • Dissolution Ratemodel
  • Particle Size Distributionmodel
  • Residual Solventmodel
  • Tablet Hardnessmodel

Go deeper

Explore Ambrisentan

Read the deeper take on agi.asView as markdown